MGMT, O-6-methylguanine-DNA methyltransferase, 4255

N. diseases: 444; N. variants: 24
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0006118
Disease: Brain Neoplasms
Brain Neoplasms
0.400 PosttranslationalModification group BEFREE Since new diagnostic methods such as methylome-based classification of brain tumors are more and more frequently performed, we aimed at comparing the suitability of calculating the MGMT promoter methylation status in a quantitative manner from the methylome profiling as compared to the classic gold standard assessment by PCR. 31784096 2020
CUI: C0006118
Disease: Brain Neoplasms
Brain Neoplasms
0.400 AlteredExpression group BEFREE Disulfiram has also been shown to inhibit the proteasomes, DNA topoisomerases, DNA methyltransferase, glutathione S-transferase P1, and O6- methylguanine DNA methyltransferase, a DNA repair protein highly expressed in brain tumors. 31084595 2019
CUI: C0006118
Disease: Brain Neoplasms
Brain Neoplasms
0.400 Biomarker group BEFREE Statistical multiscale mapping of IDH1, MGMT, and microvascular proliferation in human brain tumors from multiparametric MR and spatially-registered core biopsy. 31745125 2019
CUI: C0006118
Disease: Brain Neoplasms
Brain Neoplasms
0.400 Biomarker group BEFREE O<sup>6</sup> -methylguanine DNA methyltransferase (MGMT) promoter methylation is a predictive biomarker for benefit from alkylating chemotherapy, specifically temozolomide (TMZ), in glioblastoma, the most common malignant intrinsic brain tumor. 29480969 2018
CUI: C0006118
Disease: Brain Neoplasms
Brain Neoplasms
0.400 PosttranslationalModification group BEFREE Studies in brain tumours conclude that MGMT promoter methylation is considered a strong predictive factor for a favourable outcome for treatment with temozolomide, e.g. alkylating agent. 27492578 2017
CUI: C0006118
Disease: Brain Neoplasms
Brain Neoplasms
0.400 GeneticVariation group BEFREE Surveillance, Epidemiology, and End Results (SEER) registries currently collect data on specific required factors related to brain tumors as defined by the American Joint Commission on Cancer, including World Health Organization (WHO) grade, MGMT methylation and 1p/19q codeletion status. 27418206 2016
CUI: C0006118
Disease: Brain Neoplasms
Brain Neoplasms
0.400 PosttranslationalModification group BEFREE Analysis of MGMT promoter methylation status on intraoperative fresh tissue section from frameless neuronavigation needle biopsy of 25 patients with brain tumor. 21781444 2013
CUI: C0006118
Disease: Brain Neoplasms
Brain Neoplasms
0.400 GeneticVariation group BEFREE Recently, aberrant methylation of MLH1, MGMT and MSI were shown to be associated with mutations in genes such as BRAF, RAS and IDH1 in colon and brain tumours. 23414134 2013
CUI: C0006118
Disease: Brain Neoplasms
Brain Neoplasms
0.400 PosttranslationalModification group BEFREE The objective of this study was to retrospectively investigate MGMT promoter hypermethylation status for a series of 350 human brain tumors, including 275 gliomas of different malignancy grade, 21 glioblastoma multiforme (GBM) cell lines, and 75 non-glial tumors. 22287028 2012
CUI: C0006118
Disease: Brain Neoplasms
Brain Neoplasms
0.400 Biomarker group BEFREE MGMT silencing in tumors is mainly regulated epigenetically and in brain tumors this correlates with a better therapeutic response. 21745538 2011
CUI: C0006118
Disease: Brain Neoplasms
Brain Neoplasms
0.400 PosttranslationalModification group BEFREE A hypermethylated phenotype is a better predictor of survival than MGMT methylation in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. 21914791 2011
CUI: C0006118
Disease: Brain Neoplasms
Brain Neoplasms
0.400 Biomarker group CTD_human MGMT activity, promoter methylation and immunohistochemistry of pretreatment and recurrent malignant gliomas: a comparative study on astrocytoma and glioblastoma. 20131314 2010
CUI: C0006118
Disease: Brain Neoplasms
Brain Neoplasms
0.400 PosttranslationalModification group BEFREE Promoter methylation and expression analysis of MGMT in advanced pediatric brain tumors. 19724855 2009
CUI: C0006118
Disease: Brain Neoplasms
Brain Neoplasms
0.400 Biomarker group BEFREE (2) Persistence of prenatal MGMT deficiency into postnatal life in a sub-population of individuals may increase brain tumor risk. 17500046 2007
CUI: C0006118
Disease: Brain Neoplasms
Brain Neoplasms
0.400 Biomarker group BEFREE In this pilot study, we utilized a retroviral vector expressing methylguanine DNA methyltransferase (MGMT) to transduce hematopoietic progenitors, which were subsequently used in the setting of alkylator therapy (procarbazine, CCNU, vincristine (PCV)) for poor prognosis brain tumors. 16645619 2006
CUI: C0006118
Disease: Brain Neoplasms
Brain Neoplasms
0.400 Biomarker group BEFREE A substantial percentage of brain tumors overexpressed biomarkers associated with drug resistance, including MGMT (67%), GSTP1 (49%), and mutant p53 (41%). 16899598 2006
CUI: C0006118
Disease: Brain Neoplasms
Brain Neoplasms
0.400 Biomarker group BEFREE The O6-methylguanine-DNA methyltransferase protein (MGMT) reverses alkylation at the O6 position of guanine and we have reported the role of MGMT in the response of brain tumors to alkylating agents. 15980968 2005
CUI: C0006118
Disease: Brain Neoplasms
Brain Neoplasms
0.400 GeneticVariation group BEFREE By removing alkyl groups from the O6-position in guanine, MGMT can prevent G:C to A:T transition mutations, a type of variation frequently involving TP53 mutations in brain tumors. 15450401 2004
CUI: C0006118
Disease: Brain Neoplasms
Brain Neoplasms
0.400 GeneticVariation group LHGDN We found a significantly increased frequency of G:C to A:T mutations of the p53 gene in brain tumors having a methylated MGMT promoter compared with those having an unmethylated MGMT promoter (P < 0.05), and all the non-CpG dinucleotide G:C to A:T mutations of p53 were in samples with a methylated MGMT promoter. 12503076 2003
CUI: C0006118
Disease: Brain Neoplasms
Brain Neoplasms
0.400 GeneticVariation group BEFREE We found a significantly increased frequency of G:C to A:T mutations of the p53 gene in brain tumors having a methylated MGMT promoter compared with those having an unmethylated MGMT promoter (P < 0.05), and all the non-CpG dinucleotide G:C to A:T mutations of p53 were in samples with a methylated MGMT promoter. 12503076 2003
CUI: C0006118
Disease: Brain Neoplasms
Brain Neoplasms
0.400 PosttranslationalModification group BEFREE MGMT promoter hypermethylation is a favorable prognostic marker in patients with brain tumors treated with alkylating agents. 11773279 2002
CUI: C0006118
Disease: Brain Neoplasms
Brain Neoplasms
0.400 PosttranslationalModification group BEFREE We assessed promoter methylation of the MGMT gene in astrocytic brain tumours by methylation-specific PCR. 11577014 2001
CUI: C0006118
Disease: Brain Neoplasms
Brain Neoplasms
0.400 AlteredExpression group BEFREE The data indicate that knowledge of the expression levels of MGMT and mdr1 may be particularly useful for a more rational selection of drugs which are not influenced by these resistance genes and which have improved efficacy against human brain tumors. 10678554 1999
CUI: C0006118
Disease: Brain Neoplasms
Brain Neoplasms
0.400 Biomarker group BEFREE While the mechanism of MGMT repair has been considered to be important in the drug resistance of human brain tumors to ACNU, our present results demonstrate that beta-pol may also play an important role in the acquisition of tumor cell resistance to ACNU in human gliomas. 8878552 1996
CUI: C0006118
Disease: Brain Neoplasms
Brain Neoplasms
0.400 AlteredExpression group BEFREE Quantification of O6-methylguanine-DNA methyltransferase mRNA in human brain tumors. 8605218 1996